china currency digital- Top People also ask

Villeroi, Governing Committee of the European Central Bank: Interest rates will be cut several times next year. Francois Villeroy de Galhau, a member of the Board of Governors of the European Central Bank, said that the European Central Bank will further reduce borrowing costs in 2025, and there is still a way to go before monetary policy is no longer restrictive. "There will be more interest rate cuts next year, and many times," he said on BFM Business TV on Friday He added that the central bank did not promise the specific interest rate trajectory in advance, but was "quite satisfied with the financial market forecast". The current expectation of the swap market is to cut interest rates by about 120 basis points by the end of next year.US Secretary of State Blinken: discussed the ceasefire in Gaza with Turkish Foreign Minister Fidan. Blinken: All parties reached a broad consensus on what we want to see in Syria. We discussed the necessity of continuing efforts to crack down on the extremist organization "Islamic State". We have seen encouraging signs in the past few weeks that a ceasefire in Gaza is possible.Goldman Sachs lowered the UK's GDP growth forecast for 2024 from the previous 1.2% to 1.0%.

Jordan sold his Chicago mansion for $9.5 million, with a price reduction of 67%. According to Beiqing Sports, Michael Jordan, a famous former American professional basketball player, sold his manor mansion on the outskirts of Chicago for $9.5 million. In 2012, the public price of this mansion was $29 million. After 12 years of listing, the price was reduced by 67% and it was finally sold.Some short-term inter-bank bonds performed brilliantly. The yield of 2-year active bonds "21 interest-bearing bonds 02" went down 5bp to reach 1.1%, which was 11bp upside down from the current 1-year active bonds "24 discount bonds 67" yield of 1.21%.Guoxin Technology: Serialized chip products have been launched in the field of automotive electronic MCU. Guoxin Technology said in an investigation that the company has launched serialized chip products in the field of automotive electronic MCU in recent years, which has been welcomed by the market; Through the implementation of the strategy of "standing on the ground" and "overwhelming", this year, the company's automobile electronic MCU chip business has formed certain advantages, and obvious progress has been made in loading application and shipment volume. The product price is relatively stable, the fluctuation range is small, and the gross profit margin of the product remains relatively stable. In 2024, the company's BMS main control chip CCFC2007PT, high-end domain control chip CCFC3007PT, airbag ignition drive chip CCL1600B, etc. have all been used for loading/installing, and several manufacturers are developing at designated locations based on the above chips. In the future, with the increase of fixed-point mass production projects, shipments are expected to continue to grow.

Puli Pharmaceutical Co., Ltd.: It won the bid for the tenth batch of national centralized drug procurement. According to Puli Pharmaceutical, on December 12, Puli Pharmaceutical's meglumine gadolinium tetate injection (trade name: Puli Yingxian) and Posaconazole injection (trade name: Puli Posa) both won the bid for the tenth batch of national centralized drug procurement.Zhouming Technology: cooperated with Byte Volcano and Bean Bag to access TTS and big model question-and-answer ability. Zhouming Technology said on the interactive platform that Zhouming Technology cooperated with Microsoft, Tencent, Baidu, Iflytek, Byte Volcano and Bean Bag on the self-developed UniAvatar digital human system. Among them, in May 2024, Zhouming Digital Man was able to access Volcano Engine's TTS capability and bean bag's big model question-and-answer capability, which was suitable for digital man dialogue system and other application scenarios.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.